Compare Vanguard International High Dividend Yield ETF (VYMI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard International High Dividend Yield ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Vanguard International High Dividend Yield ETF is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard International High Dividend Yield ETF for 50 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VYMI | ZBH | |
|---|---|---|
Market Cap | $22.80B | $16.95B |
Volume | 748,441 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $107.13 | $103.98 |
52-Week Low | $82.92 | $79.58 |
Typical Hold Time | 50 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.66, up 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on international high dividend yield stocks, with recent institutional buying activity from Envestnet and Corient Private Wealth. Recent news highlights strong performance with a 29% one-year return and 14.13% five-year average annual return, supported by financials, energy, and healthcare sector exposure.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's attractive dividend yield. Key risks include global economic volatility and currency fluctuations, but institutional accumulation and sector alignment with rising rates support the investment thesis for income-focused investors seeking international diversification.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
